- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- RO7204239, Placebo, Risdiplam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
Clinical trials in Boston, Massachusetts
This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Boston
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Nonobstructive Hypertrophic Cardiomyopathy
- Interventions
- HTX-001
- Drug
- Lead sponsor
- Haya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Kansas City, Missouri • Cincinnati, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
- Conditions
- End Stage Renal Disease
- Interventions
- VasQ, Arteriovenous fistula creation for dialysis vascular access
- Device · Procedure
- Lead sponsor
- Laminate Medical Technologies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Long Beach, California • Sarasota, Florida • Atlanta, Georgia + 10 more
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 1,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 67
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 49 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Drug
- Lead sponsor
- BlossomHill Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
- Conditions
- Ulcerative Colitis
- Interventions
- LY4268989, Mirikizumab, LY4268989 Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
- Conditions
- IgA Nephropathy
- Interventions
- Placebo, LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 20
- States / cities
- Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
- Conditions
- Obesity, Overweight
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more
- Conditions
- Uncontrolled Hypertension
- Interventions
- RTN-001, Matching placebo control
- Drug
- Lead sponsor
- Retension Pharmaceuticals. Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 44
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Glendale, Arizona + 39 more